I'd say you're missing about $159 million. Last update has cash reserves of $359 million after tax removed from the latest payments. Ongoing costs outside of clinical and R and D were less than $5 million so paid for three times over just with interest on the massive cash pile.
So money is not an issue and they can fund two Ph3 trials no problem without the $50 million going to the buyback. Of course if those two fail with 2591 then the appetite to throw another $50-$100 million at a third is likely to be slim. If they hit on one or both then they'll be worth many times what they are now and all current share holders will do very well IMO
NEU Price at posting:
$12.59 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)